anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine extract, and applications thereof in preparing contraceptive drugs. The traditional Chinese medicine extract is an ethanol extract of Hylocereus undatus(Haw.)Britt.et Rose. A preparation method comprises following steps: Hylocereus undatus(Haw.)Britt.et Rose is smashed, and is extracted with an ethanol aqueous solution with a volume concentration ranging from 85 to 95% for 1 to 4 times; and an obtained extract is subjected to low temperature concentration and freeze drying so as to obtain a finished product. The traditional Chinese medicine extract possesses excellent spermicidal effect; contraception efficiency after oral administration is high; toxic and side effect is low; and the traditional Chinese medicine extract can be both used before or after sexual intercourse.
The present invention relates to controlled/extended release oral dosage forms of chromium picolinate. Chromium picolinate is a common and effective biologically active form of chromium. As such, it has beneficial nutritional and therapeutic effects including improved insulin metabolism and lipid lowering activity. The controlled dosage form of the present invention can be provided in various ways, including matrix formulations such as matrix tablets or multiparticulate formulations like micro capsules or coated pellets put into hard gelatin capsules. This provides effective drug delivery for extended periods of time, at relatively stable, optimal plasma peak values, with minimal undesirable side effects. The invention provides effective controlled/extended release oral dosage formulations of chromium picolinate and processes for their preparation.
Observational study with online survey participation highlighting outcomes recovery. The surveys can be completed by the child and parent, or if too young to participate, parent only. The survey asks how the child is doing after hospitalization within 6 months of diagnosis, and every 4 months until study end in 2024.
Patients in the Swedish series [see Clinical Studies (14)] received a wide range of cell doses per cm2 of defect. Available data on 70 of 78 patients with femoral condyle defects showed a median dose of 1.6 million cells/cm2 of defect. The middle 80% of these patients received from 0.64 million to 3.3 million cells/cm2. 

Each Carticel finished product vial contains approximately 12 million cells. Vericel provides a single vial for each defect measuring ≤ 7 cm2. Two vials of Carticel are provided for defects 7 to 14 cm2, and three vials are provided for defects > 14 cm2. This is based on Vericel's greater than 10 years of experience with Carticel.
The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
A homogeneous gas-evolving composition is provided that includes an acid, a gas-evolving acid neutralizing agent, and at least one of an inorganic carbonate, inorganic bicarbonate, alkaline peroxide, or alkaline azide. A water-soluble desiccant is homogeneously intermixed with the acid and the gas-evolving acid neutralizing agent. The desiccant is present in an amount able to absorb ambient moisture equivalent to at least 0.01 total weight percent of the composition before gas evolution of more than 50% of the theoretical gas evolution available from the composition. To confer storage stability, the acid, the gas-evolving acid neutralizing agent, and water-soluble desiccant cumulatively have a water content of less than 1 total weight percent water. Through appropriate selection of a desiccant or inclusion of a surfactant foaming agent, the composition foams upon drenching with water. The composition is particularly well suited for consistent usage of glyphosate herbicide. Plant growth inhibition is provided by wetting a plant with water and then applying the composition onto the plant. After allowing sufficient time, the composition absorbs the water and evolves gas, thereby spreading herbicide on the plant preferential to surrounding soil.
Treatment with KD will consist of 4:1 \[fat\]: \[protein + carbohydrate\] weight ratio. KD will be started as soon as the patient is ready for alimentation (while they are in neurocritical care unit). The rate of feeds will be calculated by trained dietician on service. Ketogenic diet will be continued during the entire length of ICU stay. Supplementation with vitamins, calcium and phosphorus will be done.
BACKGROUND: Sepsis is a life-threatening organ dysfunction due to a dysregulated host response to infection. Annually, sepsis leads to approx. 90.000 deaths in Germany. Risk factors include amongst others older age (>60), innate or acquired dysfunction of the immune system, and underlying chronic diseases of the lung, heart, liver, or kidneys. The manifestation of sepsis is a medical emergency, and patient outcomes depend on timely diagnosis and immediate treatment. In addition, vaccinations e.g., against pneumococci or influenza virus, are a highly effective public health tool to prevent the most common underlying infections that may lead to sepsis. However, a lack of public awareness for the relevance of vaccination and detecting sepsis as an emergency underlines the need for public health interventions that address these issues. SepWiss aims to evaluate the effects of a multimodal information campaign designed to address this lack of awareness among the risk population in Germany.
METHODS: SepWiss is an intervention at state level, consisting of a multimodal information campaign targeting risk groups in the German federal states of Berlin and Brandenburg (intervention region). Based on available evidence, various information formats were developed and implemented by outdoor advertising, social media, educational formats and through stakeholders' platforms, starting in August 2021. The control region comprises of the remaining 14 German federal states. We will analyze vaccination coverage (primary outcome), and sepsis knowledge, the ability to detect sepsis as an emergency, and attitude towards vaccination (secondary outcomes) amongst the risk population in a controlled before-after comparison. The implementation is accompanied by a mixed-method process evaluation.
DISCUSSION: SepWiss is the first project of its kind to evaluate a complex multi-faceted evidence-based information campaign with regards to the topics of vaccination coverage, and the importance of sepsis detection and prevention for the most vulnerable populations in Germany. Results will be valuable for informing further nationwide campaigns.
TRIAL REGISTRATION: German Registry for Clinical Trials: DRKS00024475. Registered February 24th, 2021.
Antiperspirant products and methods for manufacturing antiperspirant products are provided herein. In accordance with an exemplary embodiment, an antiperspirant composition comprises a container and an antiperspirant product housed within the container. The antiperspirant product comprises a first portion and a second portion. The first portion comprises an emulsion having a water phase and an oil phase. The oil phase comprises cetyl PEG/PPG-10/1 dimethicone. The second portion has a composition different from the first portion.
Participants undergo 2 tailored BBCEI sessions within 1 month. At the beginning of the first session the research nurse will present the participants with a list of common physical and social concerns. The participant will then be asked to identify 3 topics that she wants to discuss. The research nurse will discuss with the participant any relevant supportive care resources and make the appropriate referrals. At the second session the focus of the BBCEI will be on psychological and spiritual well-being.
Perioperative fluid management is crucial for patients' outcome. Series of studies have indicated that adequate fluid management optimizes the cardiac out put, improves tissue perfusion, thus decrease the risk of postoperative morbidity. Muller et al developed a "Mini-fluid challenge method " to predict fluid responsiveness and the efficacy. Fluid status and proper perfusion condition in patients undergo thoracic surgery are especially crucial for the vulnerability of lung toward fluid overload. To the best of our knowledge, the efficacy of the test was not discussed in the perioperative care in video assisted thoracic surgery. The investigators design the study to investigate the effectiveness of mini-fluid challenge test in video assisted thoracic surgery.
After recruitment, subjects will have neck strength measured as baseline in addition to doing SCAT5 for baseline and eye tracking, funding pending, in order to compare later assessment for concussion. Throughout study, subject will perform basic, unweighted and weighted neck strengthening exercises twice a week. Periodic re evaluations of neck strength will be performed in order to determine progress. Any time a subject incurs a sports related concussion, a SCAT5 assessment, and eye tracking funding pending, will be done and compared to baseline to measure severity of injury. Weekly follow ups will be done to assess duration of concussion. All measurements, assessments, and exercises are non-invasive and provide minimal risk to subjects.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two vehicle-controlled and one active-controlled U.S. clinical trials, treatment safety was monitored in 788 subjects who used twice-daily azelaic acid gel for 12 weeks (N=333) or 15 weeks (N=124), or the gel vehicle (N=331) for 12 weeks. In all three trials, the most common treatment-related adverse events were: burning/stinging/tingling (29%), pruritus (11%), scaling/dry skin/xerosis (8%) and erythema/irritation (4%). In the active-controlled trial, overall adverse reactions (including burning, stinging/tingling, dryness/tightness/scaling, itching, and erythema/irritation/redness) were 19.4% (24/124) for azelaic acid gel compared to 7.1% (9/127) for the active comparator gel at 15 weeks.

In patients using azelaic acid formulations, the following adverse events have been reported: worsening of asthma, vitiligo, depigmentation, small depigmented spots, hypertrichosis, reddening (signs of keratosis pilaris) and exacerbation of recurrent herpes labialis.

Local Tolerability Studies

Azelaic acid gel and its vehicle caused irritant reactions at the application site in human dermal safety studies. Azelaic acid gel caused significantly more irritation than its vehicle in a cumulative irritation study. Some improvement in irritation was demonstrated over the course of the clinical trials, but this improvement might be attributed to subject dropouts. No phototoxicity or photoallergenicity were reported in human dermal safety studies.
The present invention discloses a product for regulating blood fat and protecting the liver and preparation technology thereof. The product comprises hippophae rhamnoides fruit, matrimony vine, hawthorn fruit and tea polyphenol. The preparation technology of the product comprises the steps: dry hippophae rhamnoides fruit powder is prepared, matrimony vine powder and hawthorn fruit powder are prepared, and fine tea polyphenol powder with the purity of more than 65 % is used for standby; after the several kinds of prepared material powder are mixed, the granulation, the drying, the pulverization, the tabletting, the film coating operation, etc., are carried out. The present invention has the advantages that four raw materials with homology of medicine and food are reasonably combined; the ingredients with different effects are used for inhibiting lipid synthesis from the endogenous path; the lipid transformation is promoted, and the lipid transformation is inhibited from the exogenous path. The effects of regulating blood fat and protecting the liver are effectively achieved. The present invention relates to a health food and medicine which has the advantages of homology of medicine and food and little side effect.
The invention discloses a medlar mulberry hypoglycemic tea and relates to a drink. Most of diabetics with ,multiple drinking, drink boiling water and tea, but the ,multiple drinking, does not play a role in relieving the symptoms of the diabetics. The invention provides a special drink with the functions of treatment and health care, in particular a medlar mulberry hypoglycemic tea. The technical scheme of the medlar mulberry hypoglycemic tea is that: the medlar mulberry hypoglycemic tea is prepared by drying, crushing and mixing the following substances in weight ratio: 10 to 20 kilograms of medlar, 10 to 20 kilograms of mulberry, 10 to 20 kilograms of radix rehmanniae, 10 to 20 kilograms of polygonatum, 15 to 35 kilograms of liriopespicta and 15 to 35 kilograms of radix pseudostellariae. The preparation method for the medlar mulberry hypoglycemic tea comprises the following steps: accurately selecting according to the weight ratio requirement; uniformly mixing after drying and crushing; then pelleting and baking; and packaging by 3 to 5g in each bag. The tea is brewed by lukewarm boiled water with the temperature over 80 DEG C during drinking, and a user drinks the tea after 5 to 10 minutes when the medicament decoction is leached. The medlar mulberry hypoglycemic tea has the effects of supplementing qi and promoting the production of body fluid, strengthening the spleen and stomach, and moistening the heart and lung. The adjuvant therapy can be achieved due to the ,multiple drinking, of the diabetics, and the complication is prevented.
BACKGROUND: Sulfotransferase family 2B member 1 (SULT2B1) has been reported to play oncogenic role in many types of cancers. Nevertheless, the role that SULT2B1 played in ovarian cancer (OC) and the hidden molecular mechanism is obscure.
METHODS: Expression of SULT2B1 in OC was analyzed by GEPIA database. qRT-PCR and western blot (WB) was applied for the appraisement of SULT2B1 and Annexin A9 (ANXA9) in OC cell lines. The capabilities of cells to proliferate, migrate and invade were assessed with CCK-8 assay, wound healing assay, along with transwell assay. Cell apoptotic level was estimated utilizing flow cytometry. WB was employed for the evaluation of migration- and apoptosis-related proteins. Bioinformatic analysis and co-immunoprecipitation were used to predict and verify the combination of SULT2B1 and ANXA9.
RESULTS: The data showed that SULT2B1 and ANXA9 were upregulated in OC cells. SULT2B1 depletion suppressed the proliferative, migrative, and invasive capabilities of SKOV3 cells but facilitated the cell apoptosis. SULT2B1-regulated ANXA9 expression and were proved to bind to ANXA9. Additionally, ANXA9 deficiency exhibited the same impacts on cell migrative, invasive capability and apoptotic level as SULT2B1 silencing. Moreover, ANXA9 overexpression reversed the inhibitory impacts of SULT2B1 silencing on the proliferative, migrative, invasive, and apoptotic capabilities of SKOV3 cells.
CONCLUSION: In summary, SULT2B1 silencing repressed OC progression by targeting ANXA9.
This is a Phase 1, multicenter, open-label, single- and multi-dose, dose escalation study to evaluate the safety, tolerability, and preliminary efficacy of OLX10212 in the treatment of age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B. Part A is a single ascending dose study, i.e. participants will receive one intravitreal injection of OLX10212 at different dose levels and Part B is a multiple ascending dose study, i.e. participants will receive up to three intravitreal injections of OLX10212. Up to 42 individuals with AMD will be invited to participate in this study. The mechanism of action of OLX10212 holds promise to treat AMD by improving inflammation in the retina which is typically observed in patients with AMD. This is the first time OLX10212 is used in patients with AMD. Safety and tolerability of OLX10212 will be assessed via detailed ophthalmologic evaluations, vital signs, and clinical laboratory testing. In addition, plasma concentrations of OLX10212 will be measured and evaluations of the therapeutic effects of OLX10212 will be performed.

Part A uses a dose-ascending, sequential design to evaluate up to five doses of OLX10212, starting with the lowest dose of OLX10212 in a 50-μL injection. Up to six patients will be enrolled at each dose level. Each of the enrolled patients will receive a single intravitreal administration of OLX10212. The safety and tolerability evaluation period will encompass the first 14 days following OLX10212 administration. The effects of OLX10212 will be observed up to 24-weeks after injection. Based on the safety and tolerability evaluation, a decision will be made whether or not to increase the dose to the next higher dose levels for the subsequent patient cohorts. Therefore, a total of up to 30 patients (up to 5 dose levels and up to 6 patients/dose level) will be enrolled in Part A of this study.

Part B of this study uses a dose-ascending, sequential design to evaluate 2 dose levels of OLX10212 (750 and 950 μg/eye/50 μL), starting with the 750 μg/eye/50 μL dose. Three patients will initially be enrolled in each cohort. Each of the enrolled patients will receive a total of up to three intravitreal injections of OLX10212, each four weeks apart (Week 0, Week 4, and Week 8). The DLT evaluation period will encompass the first 10 weeks following the first OLX10212 administration (ending 2 weeks following the third OLX10212 administration), during which safety and tolerability will be assessed at each visit. In addition, the plasma concentrations of OLX10212 will be measured and therapeutic effects will be evaluated. A total of up to 12 patients with AMD (3 dose levels and up to 6 patients/dose level) will be invited to participate in Part B of this study.
TA-CD placebo will be administered intra muscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with blunt dissection through the capsule and penetration to the joint. Depending on the randomization of the subject, ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
Systems request and collect an opt-in from a network-connected communications device. The communications device has a unique identifier address. A server computer is connected to the network. A detector connects to a data channel over which the unique identifier address passes, and determines the unique identifier address. A dispatcher connected to and controlled by the server computer creates an opt-in request message directed to the communications device at the unique identifier address. A database is connected to the server computer. A record of the database is created for the communications device, which record includes the opt-in request message and unique identifier address. The server computer communicates the opt-in request to the communications device, and any reply message of the opt-in is received from the communications device and the database record updated accordingly. The opt-in reply message is a HIPAA authorization in a prescription drug benefit system.
The present invention provides a method for preparing heterobifunctional derivatives of polyethyleneglycol or relevant polymers with high purity and high yield. In the method, a chromatographic purification step is not needed. According to the method of the present invention, an intermediate polymer which can eliminate a group W at one terminal and has the structural formula of W-Poly-OH is provided. The intermediate polymer W-Poly-OH is converted by the method that firstly, the OH group is altered into a first functional group X, and then, the W is removed so as to generate a second hydroxyl group. Then, the latter hydroxyl group can be further converted into a second functional group Y. Therefore, needed heterobifunctional derivatives are provided.
Chronic low back pain involves high individual and social costs. Back School (BS) is a behavioural intervention designed to treat and prevent the aforementioned condition. Up to date clinical research studies have shown that transcranial direct current stimulation (tDCS) can be considered a reliable tool for chronic pain. It has been shown how tDCS is able to decrease the intensity and duration of pain modulating the activity of brain areas involved in the circuits that regulate pain, such as the thalamus, and facilitating the mechanisms inhibitors descendants of pain control. The aim of this study is to test the feasibility of combining tDCS with a behavioural intervention (i.e. BS) in subjects with chronic low back pain. Specifically, we will test their effects on low back pain intensity and participation of patients' in daily activities.
The present invention relates to high doses of macitentan, i.e. propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof, or of aprocitentan, for use in the treatment and/or prevention of pulmonary arterial hypertension (PAH). Moreover, the present invention relates to the use of high doses of macitentan, or of aprocitentan, for the manufacture of a medicament for the treatment and/or prevention of PAH, as well as to a method for the treatment and/or prevention of PAH comprising high doses of macitentan or of aprocitentan. Further, the present invention relates to a dosage regimen for the treatment and/or prevention of PAH as well as to a combination of macitentan, or of aprocitentan, with one or more phosphodiesterase type 5 (PDE5) inhibitors, prostacyclin analogues, prostacyclin receptor agonists or soluble guanylate cyclase stimulators. Therein, PAH is preferably mild or moderate PAH. Moreover, the present invention relates to a pharmaceutical composition for the treatment of PAH comprising a high dose of macitentan or of aprocitentan.
A Zhipuwuren bowel relaxing suppository for treating children constipation and a preparing method thereof are disclosed. The suppository comprises medicine powder and a substrate. Raw materials of the medicine powder comprise 200 g of immature orange fruit, 200 g of cortex magnoliae officinalis, 100 g of hemp seeds, 100 g of Chinese dwarf cherry seeds, 100 g of peach seeds, 100 g of bitter apricot seeds, 100 g of Chinese arborvitae kernel, 18 g of aloe, 4.5 g of azelaic acid and 10 g of lignin. The substrate is prepared by fully mixing vaseline, wool grease and pine tar, and heating until the mixture is melt. The mass ratio of the vaseline to the medicine powder is 7-9:1. The mass ratio of the wool grease to the medicine powder is 0.5-1:1. The mass ratio of the pine tar to the medicine powder is 0.5-1:1. Through reasonable raw material selection and ratios and an improved traditional Chinese medicine preparation form, the administration manner of traditional Chinese medicines is broadened. The suppository is an important method suitable for treating the children constipation, allows the traditional Chinese medicine to be widely accepted, and is beneficial to vigorous promotion of the traditional Chinese medicine.